Sharing research report on Genting Bhd.

Summary: Genting Bhd has 20% of TauRx which is developing an Alzheimer drug currently just completed Phase III trial. TauRx is going to announce the finding in Alzheimer's Association International Conference, which Maybank Investment thinks is likely to be successful. Potential worth of company is USD 15 billion, with Genting's part worth 12 Billion ringgit!


Attached File(s)
 Genting_071916.pdf ( 553.25k ) Number of downloads: 28

It's probably something to do with patency application.

TauRx Reports First Phase 3 Results for LMTX®
Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials
 LMTX® as monotherapy demonstrates significant reductions in disease progression in mild and moderate Alzheimer’s disease
 Strong results in both cognitive and functional tests supported by brain scan evidence of slow-down in progression of pathology
 Study misses co-primary endpoints as LMTX® as add-on therapy shows no beneficial effects
 Initial analysis from second phase 3 study in patients with mild Alzheimer’s disease confirm positive findings